Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

• Q2 revenues of $11.89 million significantly outperformed the Zacks Consensus Estimate and represented a substantial increase from $3.58 million in the year-ago quarter
• The company maintains a Zacks Rank #3 (Hold) with mixed estimate revision trends ahead of the earnings release
• Full-year fiscal outlook projects a loss of $1.04 per share on revenues of $16.06 million, with Q3 consensus expecting a loss of $0.31 per share on $1.94 million in revenues

Editas Medicine Q2 Earnings Summary

Key Financial Results

Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, significantly beating analyst expectations by 50%. The consensus estimate had projected a loss of $0.30 per share. This marks the fourth consecutive quarter the genome editing company has surpassed EPS estimates.

Revenue Performance

The company posted quarterly revenues of $11.89 million for the quarter ended June 2025, dramatically exceeding the Zacks Consensus Estimate by 524.80%. This represents substantial growth compared to year-ago revenues of $3.58 million. Editas has beaten consensus revenue estimates in three of the last four quarters.

Market Position

Editas operates in the Medical - Biomedical and Genetics industry, which currently ranks in the top 44% of 250+ Zacks industries. The stock has outperformed the broader market year-to-date.

Forward Outlook

For the coming quarter, analysts project a loss of $0.31 per share on revenues of $1.94 million. For the full fiscal year, consensus estimates anticipate a loss of $1.04 per share on revenues of $16.06 million.

The company currently holds a Zacks Rank #3 (Hold), reflecting mixed estimate revisions ahead of the earnings release.

Industry Context

Fellow industry player RenovoRx, Inc. (RNXT) is scheduled to report results on August 12, with expectations of a $0.08 per share loss and revenues of $0.73 million, representing 72.6% year-over-year growth.

The sustainability of EDIT's stock movement will largely depend on management commentary during the earnings call and subsequent estimate revisions.